Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis

被引:47
作者
Banerjee, Souvik [1 ]
Hwang, Dong-Jin [1 ]
Li, Wei [1 ]
Miller, Duane D. [1 ]
机构
[1] Univ Tennessee, Hlth Sci Ctr, Dept Pharmaceut Sci, 881 Madison Ave, Memphis, TN 38163 USA
关键词
tubulin dynamics; tubulin inhibitors; multidrug resistance; nanoparticle formulations; beta-tubulin isotypes and drug resistance; angiogenesis; vascular disrupting agent; antimitotic; PHASE-I TRIAL; SERUM-ALBUMIN NANOPARTICLES; ENDOTHELIAL-CELL MIGRATION; BOUND NAB PACLITAXEL; TESTING STAGE 1; TUMOR-VASCULATURE; TRASTUZUMAB-EMTANSINE; BIOLOGICAL EVALUATION; POLYMERIZATION INHIBITOR; ANTIANGIOGENIC ACTIVITY;
D O I
10.3390/molecules21111468
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Extensive research over the last decade has resulted in a number of highly potent tubulin polymerization inhibitors acting either as microtubule stabilizing agents (MSAs) or microtubule destabilizing agents (MDAs). These inhibitors have potent cytotoxicity against a broad spectrum of human tumor cell lines. In addition to cytotoxicity, a number of these tubulin inhibitors have exhibited abilities to inhibit formation of new blood vessels as well as disrupt existing blood vessels. Tubulin inhibitors as a vascular disrupting agents (VDAs), mainly from the MDA family, induce rapid tumor vessel occlusion and massive tumor necrosis. Thus, tubulin inhibitors have become increasingly popular in the field of tumor vasculature. However, their pharmaceutical application is halted by a number of limitations including poor solubility and toxicity. Thus, recently, there has been considerable interests in the nanoparticle drug delivery of tubulin inhibitors to circumvent those limitations. This article reviews recent advances in nanoparticle based drug delivery for tubulin inhibitors as well as their tumor vasculature disruption properties.
引用
收藏
页数:19
相关论文
共 120 条
[31]   Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme [J].
Grossmann, Kenneth F. ;
Colman, Howard ;
Akerley, Wallace A. ;
Glantz, Michael ;
Matsuoko, Yuko ;
Beelen, Andrew P. ;
Yu, Margaret ;
De Groot, John F. ;
Aiken, Robert D. ;
Olsen, Jeffery J. ;
Evans, Brent A. ;
Jensen, Randy L. .
JOURNAL OF NEURO-ONCOLOGY, 2012, 110 (02) :257-264
[32]   First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel [J].
Gupta, Neha ;
Hatoum, Hassan ;
Dy, Grace K. .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2014, 9 :209-221
[33]   TRASTUZUMAB EMTANSINE FOR THE TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER [J].
Haddley, K. .
DRUGS OF TODAY, 2013, 49 (11) :701-715
[34]  
Horner SA, 2004, MOL CANCER THER, V3, P783
[35]   Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane®) by the Pediatric Preclinical Testing Program (PPTP) [J].
Houghton, Peter J. ;
Kurmasheva, Raushan T. ;
Kolb, E. Anders ;
Gorlick, Richard ;
Maris, John M. ;
Wu, Jianrong ;
Tong, Zeen ;
Arnold, Michael A. ;
Chatterjee, Moumita ;
Williams, Terence M. ;
Smith, Malcolm A. .
PEDIATRIC BLOOD & CANCER, 2015, 62 (07) :1214-1221
[36]   Small molecule-folic acid modification on nanopatterned PDMS and investigation on its surface property [J].
Hu, Yuanyuan ;
Ma, Binjie ;
Zhang, Yingying ;
Wang, Min .
BIOMEDICAL MICRODEVICES, 2014, 16 (03) :487-497
[37]   Structural Optimization of Indole Derivatives Acting at Colchicine Binding Site as Potential Anticancer Agents [J].
Hwang, Dong-Jin ;
Wang, Jin ;
Li, Wei ;
Miller, Duane D. .
ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (09) :993-997
[38]   α-Cyclodextrin Interacts Close to Vinblastine Site of Tubulin and Delivers Curcumin Preferentially to the Tubulin Surface of Cancer Cell [J].
Jana, Batakrishna ;
Mohapatra, Saswat ;
Mondal, Prasenjit ;
Barman, Surajit ;
Pradhan, Krishnangsu ;
Saha, Abhijit ;
Ghosh, Surajit .
ACS APPLIED MATERIALS & INTERFACES, 2016, 8 (22) :13793-13803
[39]   Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth [J].
Jesus Perez-Perez, Maria ;
Priego, Eva-Maria ;
Bueno, Oskia ;
Martins, Maria Solange ;
Canela, Maria-Dolores ;
Liekens, Sandra .
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (19) :8685-8711
[40]   Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments [J].
Ji, Ya-Ting ;
Liu, Yan-Na ;
Liu, Zhao-Peng .
CURRENT MEDICINAL CHEMISTRY, 2015, 22 (11) :1348-1360